Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | CES1 | P23141 | 2/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.54 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | FNTA | P49354 | 1/20 | 0.45 |
| ▸ | FNTB | P49356 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PAM | P19021 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL367454 | 1.00 | CYP3A4 (0.66) | CYP3A4CYP2C9CES1CES2AKR1B1 | |
| SCHEMBL7923429 | 1.00 | CYP3A4 (0.66) | CYP3A4CYP2C9CES1CES2AKR1B1 | |
| SCHEMBL10073601 | 0.83 | CTBP2 (0.55) | CYP3A4CYP2C9CTBP2MEN1KMT2A | |
| SCHEMBL27840697 | 0.83 | CYP3A4 (0.52) | CYP3A4CYP2C9CES1CES2AKR1B1 | |
| SCHEMBL4740992 | 0.83 | CYP3A4 (0.52) | CYP3A4CYP2C9CES1CES2AKR1B1 | |
| SCHEMBL4740994 | 0.83 | CYP3A4 (0.52) | CYP3A4CYP2C9CES1CES2AKR1B1 | |
| SCHEMBL21081470 | 0.83 | CYP3A4 (0.52) | CYP3A4CYP2C9CES1CES2AKR1B1 | |
| SCHEMBL8921169 | 0.83 | CYP3A4 (0.66) | CYP3A4CYP2C9CES1CES2AKR1B1 | |
| SCHEMBL11401347 | 0.83 | CYP3A4 (0.66) | CYP3A4CYP2C9CES1CES2AKR1B1 | |
| SCHEMBL7336694 | 0.82 | CYP3A4 (0.59) | CYP3A4CYP2C9CES1CES2AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550732-B2 | Salt of pyrrolidin-3-yl acetic acid derivative and crystals thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-01-24 | — | — | US | disclosed |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | MEIJI SEIKA KAISHA (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9260375-B2 | Metallo-β-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| EP-2975035-A1 | SALT OF PYRROLIDIN-3-YL ACETIC ACID DERIVATIVE AND CRYSTALS THEREOF | Eisai R&D Management Co., Ltd. (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-20160002165-A1 | SALT OF PYRROLIDIN-3-YL ACETIC ACID DERIVATIVE AND CRYSTALS THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-01-07 | — | — | US | disclosed |
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | CHIKAUCHI KEN (JP) | 2012-03-22 | — | — | US | disclosed |
| US-8133882-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8133882-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2012-03-13 | — | — | US | disclosed |
| EP-1995240-B1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-1995240-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY10, P2RY12, P2RY11 | CYP3A4 400/4885CYP2C9 918/4885CES1 2868/4885 |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ME1, MGAM, GAA | CYP3A4 1281/4885CYP2C9 864/4885CES1 206/4885 |
| US-20160002165-A1 | SALT OF PYRROLIDIN-3-YL ACETIC ACID DERIVATIVE AND CRYSTALS THEREOF | ACP3, PKD1, ACMSD | CYP3A4 3138/4885CYP2C9 2968/4885CES1 4074/4885 |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY12, P2RY11, P2RY10 | CYP3A4 1005/4885CYP2C9 1479/4885CES1 3233/4885 |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | ME1, MGAM, MANBA | CYP3A4 1259/4885CYP2C9 847/4885CES1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.